Physician profile
Meyer A Horn
NPI 1831139344
$119,522.55
in general payments reported to CMS, 2019-2025
36 companies · $2,263 in 2025
The $2,263 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $15K · 2021: $20K · 2022: $11K · 2023: $14K · 2024: $7,242 · 2025: $2,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $6,820 · Consulting Fee: $2,259 · Education: $95.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,175.00 |
| Food and Beverage | $6,820.48 |
| Consulting Fee | $2,258.75 |
| Education | $95.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $102,562.65 | 2019-2025 | |
| Janssen Biotech, INC. | $3,286.36 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $2,757.22 | 2019-2025 | Adbry |
| Genzyme Corporation | $1,854.36 | 2019-2025 | |
| Almirall LLC | $938.36 | 2019-2020 | |
| Prugen, INC. Pharmaceuticals | $811.16 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $754.07 | 2019-2024 | Dupixent |
| Pfizer INC. | $730.06 | 2019-2025 | |
| Lilly USA, LLC | $715.37 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $685.57 | 2019-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $676.95 | 2019-2025 | |
| Ucb, INC. | $581.31 | 2019-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $437.26 | 2019-2025 | Oracea, Epsolay, Aklief |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $377.74 | 2019-2025 | Cabtreo, Jublia, Siliq |
| Incyte Corporation | $264.75 | 2022-2025 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $250.02 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.55 | 2023-2025 | Cyltezo, Spevigo |
| Dermavant Sciences, INC. | $189.39 | 2022-2024 | Vtama |
| Mayne Pharma Commercial LLC | $187.83 | 2019-2025 | |
| Allergan, INC. | $187.42 | 2019-2022 | |
| Amgen INC. | $182.15 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $156.04 | 2023-2025 | Zoryve |
| Dermira, INC. | $112.87 | 2019 | |
| Vyne Pharmaceuticals INC. | $91.03 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $89.90 | 2023-2025 | Idacio |
| E.R. Squibb & Sons, L.L.C. | $83.01 | 2023-2025 | Sotyktu |
| Celgene Corporation | $68.84 | 2019 | |
| Epi Health, LLC | $67.46 | 2019-2022 | |
| Mylan Pharmaceuticals INC. | $55.16 | 2019 | |
| Organon LLC | $52.34 | 2025 | Vtama |
| Mission Pharmacal Company | $34.69 | 2019 | |
| Sandoz INC. | $21.33 | 2019 | |
| Organogenesis INC. | $18.76 | 2023 | Puraply |
| Biofrontera INC. | $16.79 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Dusa Pharmaceuticals, INC. | $16.46 | 2019 | |
| Encore Dermatology INC. | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meyer Horn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.